Login to Your Account



TARGETS SICKLE CELL, BETA-THALASSEMIA

Genome-editing tech lures Biogen; Sangamo rises on $314M deal

By Jennifer Boggs
Managing Editor

Friday, January 10, 2014
A month after reporting promising preclinical data from its zinc finger nuclease (ZFN) therapy in beta-thalassemia at the American Society of Hematology (ASH) meeting in New Orleans, Sangamo Biosciences Inc. licensed rights to the technology in a collaboration with Biogen Idec Inc. worth up to about $314 million total.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription